Policy & Regulation
Sanofi reports positive phase 3 results for Nexviazyme in infantile-onset Pompe disease
30 June 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Tuesday that its Phase 3 Baby-COMET study met its primary endpoint, with treatment-naïve infant...
Zelluna awarded NOK16m research grant for Phase 1 cancer study
30 June 2026 - Zelluna ASA (OSE:ZLNA), a Norway-based company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cells for the treatment of cancer, said on T...
AMR Clinical acquires ClinOhio Research Services
30 June 2026 - AMR Clinical, a US-based, multi-site research company, said on Monday it has acquired ClinOhio Research Services (ClinOhio), a multi-therapeutic research site founded in 2017 and based ...
Nuvation Bio's taletrectinib Marketing Authorisation Application for advanced ROS1-positive non-small cell lung cancer treatment validated in UK
30 June 2026 - Nuvation Bio (NYSE: NUVB), a New York-based global oncology company involved in cancer treatment, announced on Monday that the Medicines and Healthcare products Regulatory Agency (MHRA)...
Viatris announces VR-205 Phase 3 Study results in Japanese adults with primary immunoglobulin A nephropathy
30 June 2026 - Viatris Inc. (NASDAQ: VTRS), a US-based global healthcare company, announced on Monday positive top-line results from a Phase 3 clinical trial evaluating the efficacy and safety of VR-2...
Grünenthal completes Nociceptin Receptor (NOP) Agonist Phase I trial
30 June 2026 - Grünenthal, a Germany-based pharmaceutical company, announced on Monday that the company has successfully concluded a Phase I trial evaluating the safety and tolerability of its pr...